# SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer

> **NCT06422156** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 73 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **RADIATION:** Stereotactic body radiation
- **DRUG:** Nimotuzumab
- **DRUG:** mono-chemotherapy

## Key facts

- **NCT ID:** NCT06422156
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2024-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06422156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06422156, "SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06422156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*